Watch the recording It can be challenging to develop an economic model in rare diseases that optimises HTA and reimbursement outcomes. It can be difficult to fully capture the effects of the disease and the benefits of treatment whilst using sufficiently robust data...
Written by Jenna Stephens (Systematic Review Analyst) and Neil Webb (Head of Systematic Review) Evidence-based medicine and its standard practice When Archibald Cochrane formulated his vision for evidence-based medicine (EBM), it was driven by an absence of reliable,...
Written by Tom Macmillan, Consultant – Systematic Review The NICE Medical Technologies Evaluation Programme (MTEP) evaluates novel medical devices and diagnostics for use within the National Health Service (NHS). There are currently 3 outputs from the...
Written by Chris Hellmund (Senior Medical Writer) and Neil Webb (Head of Systematic Review) A poster on this topic was presented at ISPOR Europe 2019. This blog post provides an overview of our findings.The abstract is available here. In previous blog posts, we...
Written by Chris Hellmund, Senior Medical Writer In a previous post, we discussed the origins of the NICE Highly Specialised Technologies (HST) process for the evaluation of therapies for rare diseases. In this blog, we examine the key differences between the Single...